Sionna Therapeutics (SION) Research & Development (2024 - 2026)

Sionna Therapeutics has disclosed Research & Development across 3 years of filings, most recently posting $19.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $19.0 million, up 38.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.6 million (up 7.94% YoY), and the FY2025 annual result was $60.3 million, up 5.19% from the prior year.
• Research & Development came in at $19.0 million for Q1 2026 at Sionna Therapeutics, up from $15.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $24.6 million in Q3 2024 to a low of $8.2 million in Q2 2024.
• The 3-year median for Research & Development is $15.2 million (2025), against an average of $15.2 million.
• Peak annual rise in Research & Development reached 86.85% in 2025, while the deepest fall reached 34.73% in 2025.
• Sionna Therapeutics' Research & Development stood at $14.3 million in 2024, then gained by 6.42% to $15.2 million in 2025, then climbed by 25.02% to $19.0 million in 2026.
• The last three Research & Development figures came in at $19.0 million (Q1 2026), $15.2 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.